JP Morgan Chase
CLYM

JP Morgan Chase’s Climb Bio CLYM Stock Holding History

JP Morgan Chase’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$196K Buy
14,650
+14,604
+31,748% +$151K ﹤0.01% 5637
2026
Q1 		$301 Hold
46
– – ﹤0.01% 7224
2025
Q4 		$184 Sell
46
-21,966
-100% -$52.7K ﹤0.01% 7165
2025
Q3 		$44.2K Sell
22,012
-188,110
-90% -$349K ﹤0.01% 6276
2025
Q2 		$261K Sell
210,122
-96,302
-31% -$120K ﹤0.01% 5105
2025
Q1 		$374K Buy
306,424
+14,628
+5% +$23.7K ﹤0.01% 4946
2024
Q4 		$525K Buy
291,796
+279,020
+2,184% +$1.01M ﹤0.01% 5005
2024
Q3 		$65K Buy
12,776
+9,672
+312% +$68.4K ﹤0.01% 5893
2024
Q2 		$22.1K Buy
+3,104
New +$20.7K ﹤0.01% 6110
2024
Q1 		– Sell
-1
Closed -$3 – 7962
2023
Q4 		$3 Buy
+1
New +$3 ﹤0.01% 7464
2022
Q2 		– Sell
-2,829
Closed -$24K – 6959
2022
Q1 		$24K Sell
2,829
-205,199
-99% -$1.91M ﹤0.01% 6039
2021
Q4 		$2.18M Buy
208,028
+4,590
+2% +$68.4K ﹤0.01% 3796
2021
Q3 		$3.66M Buy
+203,438
New +$4.2M ﹤0.01% 3307

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase's CLYM Position: Q2 2026 in Review

JP Morgan Chase increased its Climb Bio (CLYM) stake by 31,748% in Q2 2026, buying an estimated $151K and bringing the position to 14,650 shares worth $196K. The position accounts for ﹤0.01% of the portfolio, ranked #5637.

JP Morgan Chase first reported a position in CLYM in Q3 2021 and has held it in 13 quarters since. The position peaked at $3.66M in Q3 2021. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • JP Morgan Chase held 14,650 shares of Climb Bio worth $196K as of Q2 2026.
  • JP Morgan Chase bought 14,604 Climb Bio shares in Q2 2026, an estimated $151K.
  • Climb Bio made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5637 holding.
  • JP Morgan Chase first reported a position in Climb Bio in Q3 2021 and has held it in 13 quarters since.
  • JP Morgan Chase's Climb Bio position peaked at $3.66M in Q3 2021.
  • 109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.